Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Zeng Li *Laboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Department of Bioengineering Sciences (DBIT), Vrije Universiteit Brussel (VUB), Brussels, Belgium.ORCID 0000-0001-9368-5827
Bo-Kyung Jin *Laboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Department of Bioengineering Sciences (DBIT), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Emily Estefania Timaury MorenoLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Department of Bioengineering Sciences (DBIT), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Andrés Álvarez-RodríguezLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Department of Bioengineering Sciences (DBIT), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Jo A Van GinderachterLaboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Department of Bioengineering Sciences (DBIT), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Magdalena RadwanskaLaboratory for Biomedical Research, Department of Environmental Technology, Food Technology and Molecular Biotechnology, Ghent University Global Campus, Incheon, South Korea.
Yann G-J SterckxLaboratory of Medical Biochemistry (LMB) and the Infla-Med Centre of Excellence, Department of Pharmaceutical Sciences, University of Antwerp, Antwerp, Belgium.ORCID 0000-0002-7420-0983
Benoit Stijlemans *Laboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Department of Bioengineering Sciences (DBIT), Vrije Universiteit Brussel (VUB), Brussels, Belgium.
Stefan Magez *Laboratory of Cellular and Molecular Immunology, Brussels Center for Immunology (BCIM), Department of Bioengineering Sciences (DBIT), Vrije Universiteit Brussel (VUB), Brussels, Belgium.ORCID 0000-0003-3760-7968
Funding
European Union's Horizon 2020 research and innovation program 101000467Strategic Research Program SRP47Strategic Research Program SRP83UGhent BOF funding bof.baf.2024.0712.01
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development of a camelid single-domain antibody-based antigen detection assay for the pan-specific diagnosis of active human and animal · full record | OpenQuestion